American Society of Clinical Oncology 47th Annual ... - ABCSG

Saturday, June 4, 2011SATURDAYBrd. 2D Vascular hemodynamic profiles of vestibular schwannomas andglioblastoma using MRI. (Abstract #2047)S. R. Plotkin, D. Jennings, K. Mouridsen, K. E. Emblem, A. G. SorensenBrd. 2E FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET followinghypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV),and temozolomide (TMZ) for glioblastoma (GBM). (Abstract #2048)C. Grommes, S. Karimi, K. Beal, T. A. Chan, L. E. Abrey, P. H. Gutin, A. M. OmuroBrd. 2F CD44 as a prognostic and predictive marker for GBM. (Abstract #2049)B. D. Vaillant, K. Bhat, E. P. Sulman, V. Balasubramaniyan, S. Wang, K. D. Aldape,H. ColmanBrd. 2G A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma(HGG). (Abstract #2050)J. Drappatz, J. J. Raizer, D. Schiff, A. S. Chi, T. Batchelor, S. M. Snodgrass,E. C. Quant, A. D. Norden, R. Beroukhim, S. A. Grimm, L. M. Doherty,A. S. Ciampa, D. C. LaFrankie, S. Ruland, M. Gerard, S. Hammond, P. Y. WenBrd. 3A Concurrent temozolomide and radiation as the initial treatment for anaplasticglioma. (Abstract #2051)C. Tham, S. See, S. Tan, W. Ng, K. H. Lim, J. Thomas, E. ChuaBrd. 3B Randomized phase II study of neoadjuvant bevacizumab and irinotecanversus bevacizumab and temozolomide followed by concomitantchemoradiotherapy in newly diagnosed primary glioblastoma multiforme.(Abstract #2052)K. F. Hofland, S. Hansen, M. Sorensen, H. P. Schultz, A. Muhic, S. Engelholm,A. Ask, C. Kristiansen, C. Thomsen, H. Skovgaard Poulsen, U. N. LassenBrd. 3C Prognostic factors in patients with WHO grade 3 gliomas: The ClevelandClinic experience. (Abstract #2053)N. Hashemi-Sadraei, H. S. Bawa, A. Satra, G. Rahmathulla, M. Patel, G. Stevens,T. M. Tekautz, L. A. Rybicki, D. M. Peereboom, J. H. Suh, R. Weil,M. A. Vogelbaum, G. Barnett, M. S. AhluwaliaBrd. 3D Phase l study of sorafenib in combination with radiation therapy andtemozolomide for the first-line treatment of patients with high-grade glioma.(Abstract #2054)A. F. Hottinger, A. Ben Aissa, A. Bodmer, D. Squiban, N. Dunkel, N. Maradan,M. I. Vargas, D. C. Weber, E. Brendel, P. DietrichBrd. 3E Upfront bevacizumab with temozolomide or with temozolomide andirinotecan for unresectable or multifocal glioblastoma. (Abstract #2055)E. Lou, D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan,S. G. Turner, A. L. Sumrall, L. Bailey, H. S. Friedman, J. J. VredenburghBrd. 3F Phase II clinical trial of bortezomib and bevacizumab combination inrecurrent glioblastoma. (Abstract #2056)D. A. Bota, Z. Eroglu, D. A. Reardon, B. D. Fu, J. Norfleet, A. Desjardins,M. E. Linskey, K. Peters, H. S. Friedman, J. J. VredenburghBrd. 3G Temozolomide-based chemoradiation in naive pure and mixed anaplasticastrocytoma: Long-term results of a phase II study. (Abstract #2057)S. Chiesa, G. Chiloiro, S. Manfrida, A. Mangiola, G. R. D’Agostino, G. Mantini,A. Albanese, P. De Bonis, C. Anile, M. BalducciBrd. 3H Prognostic factors in newly diagnosed glioblastoma: Have we missedgender? (Abstract #2058)E. Franceschi, A. Tosoni, S. Bartolini, L. Scopece, L. Lombardo, R. Poggi,V. Mazzocchi, L. La Torre, M. Ermani, A. A. BrandesBrd. 4A Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newlydiagnosed glioblastoma. (Abstract #2059)F. Bach, M. Westphal, OSAG-101 Study Group98